ArticlePloS one2011
Inhibition of MLC phosphorylation restricts replication of influenza virus--a mechanism of action for anti-influenza agents.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Post-translational modification networks as master regulators of influenza virus replication, host adaptation, and immune evasion.Frontiers in immunology · 2026Review
- Rho-GTPases subfamily: cellular defectors orchestrating viral infection.Cellular & molecular biology letters · 2025Review
- Role of ROCK signaling in virus replication.Virus research · 2023Review
- ROCK1/MLC2 inhibition induces decay of viral mRNA in BPXV infected cells.Scientific reports · 2022Article
- In vitro anti-influenza assessment of anionic compounds ascorbate, acetate and citrate.Virology journal · 2022Article
- Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea.Journal of personalized medicine · 2021Article
- Role of Post-translational Modifications in Influenza A Virus Life Cycle and Host Innate Immune Response.Frontiers in microbiology · 2020Review
- Experimental validation and computational modeling of anti-influenza effects of quercetin-3-O-α-L-rhamnopyranoside from indigenous south African medicinal plant Rapanea melanophloeos.BMC complementary and alternative medicine · 2019Article
- Influenza Hemagglutinin Modulates Phosphatidylinositol 4,5-Bisphosphate Membrane Clustering.Biophysical journal · 2019Article
- Autophagy: The multi-purpose bridge in viral infections and host cells.Reviews in medical virology · 2018Review
- Advancements in Host-Based Interventions for Influenza Treatment.Frontiers in immunology · 2018Review
- Screening differential miRNAs responsible for permeability increase in HUVECs infected with influenza A virus.PloS one · 2017Article
- Review
- Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β activation.The Journal of biological chemistry · 2014Article
- Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-β-dependent vascular endothelial cadherin tyrosine phosphorylation.Cardiovascular diabetology · 2014Article
- Simvastatin modulates cellular components in influenza A virus-infected cells.International journal of molecular medicine · 2014Article
- Rho'ing in and out of cells: viral interactions with Rho GTPase signaling.Small GTPases · 2014Review
- Mechanisms of action and efficacy of statins against influenza.BioMed research international · 2014Review
- Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus.Antimicrobial agents and chemotherapy · 2013Article
- Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo.International journal of nanomedicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A viruses are a severe threat worldwide, causing large epidemics that kill thousands every year. Prevention of influenza infection is complicated by continuous viral antigenic changes. Newer anti-influenza agents include MEK/ERK and protein kinase C inhibitors; however, the downstream effectors of these pathways have not been determined. In this study, we identified a common mechanism for the inhibitory effects of a significant group of anti-influenza agents. Our studies showed that influenza infection activates a series of signaling pathways that converge to induce myosin light chain (MLC) phosphorylation and remodeling of the actin cytoskeleton. Inhibiting MLC phosphorylation by blocking RhoA/Rho kinase, phospholipase C/protein kinase C, and HRas/Raf/MEK/ERK pathways with the use of genetic or chemical manipulation leads to the inhibition of influenza proliferation. In contrast, the induction of MLC phosphorylation enhances influenza proliferation, as does activation of the HRas/Raf/MEK/ERK signaling pathway. This effect is attenuated by inhibiting MLC phosphorylation. Additionally, in intracellular trafficking studies, we found that the nuclear export of influenza ribonucleoprotein depends on MLC phosphorylation. Our studies provide evidence that modulation of MLC phosphorylation is an underlying mechanism for the inhibitory effects of many anti-influenza compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.